Abstract
Background The limited efficacy of the two malaria vaccines, RTS,S/AS01 and R21/Matrix M, which were recently approved vaccines by the World Health Organization, highlights the need for alternative vaccine candidate genes beyond these pre-erythrocytic-based vaccines. Plasmodium falciparum Reticulocyte Binding Protein Homologue 5 (Pfrh5) is a potential malaria vaccine candidate, given its limited polymorphism compared to other parasite’s blood stage antigens. This study evaluated the genetic diversity of the Pfrh5 gene among parasites from regions with varying malaria transmission intensities in Mainland Tanzania, to generate baseline data for this potential malaria vaccine candidate.
Methods This study utilized secondary data of 697 whole-genome sequences from Mainland Tanzania, which were generated by the MalariaGEN Community Network. The samples which were sequenced to generate the data were collected between 2010 and 2015 from five districts within five regions of Mainland Tanzania, with varying endemicities (Morogoro urban district in Morogoro region, Muheza district in Tanga region, Kigoma-Ujiji district in Kigoma region, Muleba district in Kagera region, and Nachingwea district in Lindi region). The genetic diversity of the Pfrh5 gene was assessed using different genetic metrics, including Wright’s fixation index (FST), Wright’s inbreeding coefficient (Fws), Principal Component analysis (PCA), nucleotide diversity (π), haplotype network, haplotype diversity (Hd), Tajima’s D, and Linkage disequilibrium (LD).
Results Of the sequences used in this study (n=697), 84.5% (n = 589/697) passed quality control and 313 (53.1%) were monoclonal, and these monoclonal sequences were used for haplotype diversity and haplotype network analysis. High within-host diversity (Fws <0.95) was reported in Kigoma-Ujiji (60.7%), Morogoro urban (53.1%), and Nachingwea (50.8%), while Muleba (53.9%) and Muheza (61.6%) had low within host diversity (Fws≥0.95). PCA did not show any population structure across the five districts and the mean FST value among the study populations was 0.015. Low nucleotide diversity values were observed across the study sites with the mean nucleotide diversity of 0.00056. A total of 27 haplotypes were observed among the 313 monoclonal samples. The Pf3D7 was detected as Hap_1, and it was detected in 16/313 (5.1%) sequences, and these sample sequences were from Muheza (62.5%, n=10/16), Kigoma-Ujiji (18.8%, n=3/16), and Muleba (18.8%, n=3/16). Negative Tajima’s D values were observed among the parasite populations in all the study sites.
Conclusion In this study, we observed low levels of polymorphism in the pfrh5 gene, as it exhibited low nucleotide and haplotype diversity, a lack of population structure and negative Tajima’s D values as signatures of purifying selection. This study provides an essential framework of the diversity of the Pfrh5 gene to be considered in development of the next generation malaria vaccines. Robust and intensive studies of this and other candidate genes are required for characterization of the parasites from areas with varying endemicity, and are crucial to support the prioritization of the Pfrh5 gene for potential inclusion in a broadly cross-protective malaria vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This publication used data from the MalariaGEN Plasmodium falciparum Community Project as described in an open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. This study was part of AJK`s internship program at NIMR which was supported in whole by the Bill & Melinda Gates Foundation [grant number 002202]. Under the grant conditions of the Foundation a Creative Commons Attribution 4.0. Generic License has already been assigned to the Author, Accepted Manuscript version that might arise from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- WHO
- World Health Organization
- SSA
- Sub Saharan Africa
- CSP
- Circumsporozoite surface protein
- MSP 1
- Merozoite surface protein 1
- TES
- Therapeutic efficacy studies
- CSS
- Cross sectional studies
- DDH
- Designated district hospital
- WGS
- Whole genome sequence
- VCF
- Variant call format
- LD
- Linkage disequilibrium
- PCA
- Principal component analysis
- PfRH5
- Plasmodium falciparum reticulocyte binding homologue 5
- NIMR
- National Institute for Medica Research
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.